DLX-001 is under clinical development by Delix Therapeutics and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DLX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DLX-001 overview

DLX-001 is under development for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD) and neuropsychiatric diseases. It is administered through oral route. The drug candidate is a non-hallucinogenic psychoplastogen psychedelic.

Delix Therapeutics overview

Delix Therapeutics is a biotechnology company that discovers and develops small molecule drugs for the treatment of psychiatric and neurological. Its product pipeline include in psychoplastogens for treatment-resistant depression, substance use disorder, PTSD (post-traumatic stress disorder), cognitive impairment in schizophrenia, neurodegeneration, and other central nervous system disorders. Its pipeline serves to cure patients suffering from depression, anxiety and post-traumatic stress disorders Delix Therapeutics is headquartered in Menlo Park, California, the US.

For a complete picture of DLX-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.